Which medication is appropriate to prescribe for a 26-year-old pregnant woman in her third trimester with major depressive disorder and social anxiety disorder who is increasingly isolated and has poor self‑care?

Prescribe Sertraline as First-Line Pharmacotherapy

For this 26-year-old woman in her third trimester with moderate-to-severe major depressive disorder and social anxiety disorder showing increasing isolation and poor self-care, I recommend initiating sertraline as the preferred antidepressant medication. Given the severity indicated by worsening isolation and self-care deterioration, pharmacotherapy is warranted over psychotherapy alone at this stage 1.

Why Sertraline Specifically

Among SSRIs, sertraline is the most consistently recommended first-line agent for new episodes of depression during pregnancy 2. The international guideline review found consensus across multiple countries preferring sertraline for new episodes in pregnancy, while older SSRIs (fluoxetine, sertraline, citalopram) collectively show the best safety profile with no clear teratogenic risk 3, 4.

Rationale for Pharmacotherapy Over Psychotherapy Alone

The stepped-care approach from APA/ACOG guidelines indicates that moderate-to-severe depression warrants evidence-based treatment beyond monitoring 1. Your patient's deteriorating function (increasing isolation, poor self-care) signals moderate-to-severe illness requiring immediate intervention. While cognitive behavioral therapy and antidepressants show roughly equal efficacy in general populations 1, the third trimester timing makes immediate symptom control critical for maternal and fetal wellbeing - untreated depression carries risks of impaired feto-placental function, premature delivery, and low fetal growth 4.

Key Clinical Considerations

Dosing in Third Trimester

• Start at standard therapeutic doses (sertraline 50mg, titrating to 100-150mg as needed)
• Be aware that pregnancy-related pharmacokinetic changes may require dose increases in late pregnancy due to increased hepatic metabolism and renal clearance 5
• Monitor clinical response closely; dose adjustments are commonly needed in the third trimester

Safety Profile

• The evidence provides reassurance that prenatal antidepressant exposure is unlikely to substantially increase risk of ASD or ADHD - observed associations are largely explained by confounding factors (maternal illness severity, genetics) rather than medication exposure itself 1
• Neonatal withdrawal symptoms may occur but are typically self-limiting with favorable outcomes 4
• Plan for neonatal observation after delivery 2

Avoid Paroxetine

Paroxetine is specifically not preferred for new episodes during pregnancy 2, though switching from paroxetine if already established is discouraged due to relapse risk.

Common Pitfalls to Avoid

1. Don't delay treatment waiting for psychotherapy availability - the third trimester window is narrow and untreated maternal depression poses immediate risks
2. Don't underdose - pregnancy increases drug clearance, particularly in the third trimester 5
3. Don't abruptly discontinue due to pregnancy concerns - this exposes the patient to serious relapse risk 4

Breastfeeding Counseling

Encourage breastfeeding continuation if she chooses to breastfeed postpartum while on sertraline 2. The benefits of treating maternal depression and enabling breastfeeding outweigh minimal infant exposure through breast milk.

Monitoring Plan

• Weekly clinical assessment initially to evaluate response and tolerability
• Screen for worsening symptoms, suicidal ideation, and medication side effects
• Coordinate with obstetrics for neonatal monitoring plan at delivery
• Prepare for potential postpartum dose adjustment as pharmacokinetics normalize